Safety profile of cariprazine in patients with predominant negative symptoms of schizophrenia

被引：0
|
作者：
Szatmari, B. [1 ]
Barabassy, A. [1 ]
Laszlovszky, I. [1 ]
Harsanyi, J. [1 ]
Szalai, E. [1 ]
Reti-Gyorffy, D. [1 ]
Nemeth, G. [1 ]
机构：
[1] Gedeon Richter Plc, Div Med, Budapest, Hungary
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2017年 / 27卷
关键词：
D O I：
10.1016/S0924-977X(17)31609-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.b.021
引用
收藏
页码：S903 / S903
页数：1
相关论文
共 50 条
  • [1] Cariprazine vs risperidone efficacy on predominant negative symptoms of schizophrenia: post hoc analysis of negative symptoms subdomains
    Laszlovszky, I.
    Barabassy, A.
    Szatmari, B.
    Harsanyi, J.
    Szalai, E.
    Nemeth, G.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S902 - S903
  • [2] Schizophrenia: Cariprazine reduces Negative Symptoms
    Krome, Susanne
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2017, 142 (10) : 717 - +
  • [3] Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone
    Nemeth, Bertalan
    Molnar, Anett
    Akehurst, Ron
    Horvath, Margit
    Koczian, Kristof
    Nemeth, Gyorgy
    Gotze, Arpad
    Voko, Zoltan
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2017, 6 (08) : 639 - 648
  • [4] Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial
    Debelle, M.
    Nemeth, G.
    Szalai, E.
    Szatmari, B.
    Harsanyi, J.
    Barabassy, A.
    Laszlovszky, I.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S510 - S510
  • [5] Clinical improvement of patients with predominant negative symptoms of schizophrenia: Post-hoc analysis of cariprazine versus risperidone
    Sebe, B.
    Barabassy, A.
    Laszlovszky, I.
    Szatmari, B.
    Harsanyi, J.
    Acsai, K.
    Earley, W.
    Patel, M.
    Nemeth, G.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S275 - S275
  • [6] Efficacy of cariprazine in predominant negative symptoms of schizophrenia - post hoc analyses against different comparators
    Szatmari, B.
    Barabassy, A.
    Laszlovszky, I.
    Harsanyi, J.
    Acsai, K.
    Reti-Gyorffy, D.
    Earley, W.
    Patel, M.
    Nemeth, G.
    [J]. EUROPEAN PSYCHIATRY, 2018, 48 : S105 - S105
  • [7] PREDOMINANT NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
    Millier, A.
    Aballea, S.
    Toumi, M.
    Lancon, C.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A93 - A93
  • [8] Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition
    Marder, S.
    Laszlovszky, I.
    Szalai, E.
    Szatmari, B.
    Harsanyi, J.
    Barabassy, A.
    Debelle, M.
    Durgam, S.
    Bitter, I.
    Nemeth, G.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S550 - S550
  • [9] EVOLUTION OF PRESENCE OF PREDOMINANT NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
    Refai, T.
    Millier, A.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A766 - A766
  • [10] Cariprazine as Monotherapy for the Treatment of Predominant Negative Symptoms of Patients with Schizophrenia: A Double-Blind, Active Comparator-Controlled Trial
    Debelle, Marc
    Kahn, Rene
    Laszlovszky, Istvan
    Szalai, Erzsebet
    Nemeth, Gyoergy
    Szatmari, Balazs
    Harsanyi, Judit
    Barabassy, Gota
    Durgam, Suresh
    Fleischhacker, Wolfgang
    [J]. NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S235 - S236
12345